Karyopharm Therapeutics Total Liabilities

Karyopharm Therapeutics (KPTI) currently reports a total liabilities of $400M as of March 2026. That compares with $330M in the prior-year period — up 19.0% year over year. Use the charts on this page to explore Karyopharm Therapeutics's total liabilities history and peer comparisons.

Karyopharm Therapeutics's total liabilities increased from $330M to $400M — a 19.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Karyopharm Therapeutics reported $400M in total liabilities as of March 2026. That compares with $330M in the prior-year period — up 19.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $400M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Karyopharm Therapeutics, and consider following KPTI for alerts when major investors trade the stock.

Karyopharm Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $400M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KPTI with unrelated industries.